| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The incidence of thyroid cancer has been increasing worldwide. Although most papillary thyroid carcinomas have a good prognosis, a small but certain fraction shows aggressive behavior. Therefore, a novel and well-performing molecular marker is needed.
In the present study, we examined whether mutations in the promoter region of the telomerase reverse transcriptase (TERT) gene could serve as a molecular marker as described above.
TERT promoter mutations were found to be useful as a prognostic molecular marker for thyroid cancer and were associated with resistance to radioiodine therapy. We also found that some TERT promoter mutation-negative cases expressed TERT mRNA, and those had a higher recurrence rate.
|
